Research programme: antibiotics - NAICONS

Drug Profile

Research programme: antibiotics - NAICONS

Alternative Names: NAI 414; nai 414-A; NAI 414-A; nai 414-B; NAI 414-B; NAI 603; Nai 603; Orthoformimycin; PUM

Latest Information Update: 02 Dec 2015

Price : $50

At a glance

  • Originator NAICONS
  • Class Anti-infectives
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Peptide elongation factor G inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections; Gram-positive infections; Solid tumours

Most Recent Events

  • 02 Dec 2015 Preclinical trials in Solid tumours in Italy (unspecified route)
  • 02 Dec 2015 Preclinical trials in Gram-positive infections in Italy (IV)
  • 02 Dec 2015 Preclinical trials in Gram-negative infections in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top